



Module 1

Basic principles and overview of training modules

ICH E17: General principles for planning and design of Multi-Regional Clinical Trials

Legal Notice

- This presentation is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

ICH HARMONISED GUIDELINE

General Principles for Planning and Design of Multi-Regional Clinical Trials E17 (*FINAL*)

November 16th, 2017


ICH E17 guideline

- Work started in June 2014
- Finalised in November 2017
 - **Multi-Regional Clinical Trial (MRCT) = a clinical trial conducted in more than one region under a single protocol.**
 - **Region = a geographical region, country or regulatory region.**




Why was the E17 Guideline drafted?

- Historically, clinical trials of a new medicine were often performed separately in different regulatory regions to fulfil the requirements of each region.



- More recently, global regulatory strategies are also used to plan and conduct studies




The purpose of E17 is to describe general principles and strategic programme issues for the planning and design of multi-regional clinical trials to ensure that data from such trials can be accepted by regulatory authorities across regions and countries as the primary source of evidence, to support marketing approval of medicinal products

Which are the advantages associated with MRCTs according to E17?

- **Facilitates a more efficient development of new medicines and increase the possibility of having the new medicine approved in several different regions at the same time**
- **Efficient way to be able to recruit a sufficient number of trial subjects within a reasonable timeframe**
- **Provides an opportunity to learn more about how treatment effects can vary between different regions and populations and may explain reasons for differences**

Which challenges need to be considered when planning an MRCT?



**Conducting an MRCT may be possible in spite of these concerns!
Challenges at the planning stage may translate into new knowledge!**

How can E17 help to handle the challenges?

2.1 Strategy-related Issues

2.1.1	<i>The Value of MRCTs in Drug Development</i>	3
2.1.2	<i>Good Clinical Practice (GCP) Requirements and MRCTs</i>	6
2.1.3	<i>Scientific Consultation Meetings with Regulatory Authorities</i>	6

2.2 Clinical Trial Design and Protocol-related Issues

2.2.1	<i>Pre-consideration of Regional Variability and its Potential Impact on Efficacy and Safety</i>	7
2.2.2	<i>Subject Selection</i>	9
2.2.3	<i>Selection of Doses for Use in Confirmatory MRCTs</i>	10
2.2.4	<i>Choice of Endpoints</i>	11
2.2.5	<i>Sample Size Planning</i>	13
2.2.6	<i>Collecting and Handling of Efficacy and Safety Information</i>	18
2.2.7	<i>Statistical Analysis Planning</i>	20
2.2.8	<i>Selection of Comparators</i>	23
2.2.9	<i>Handling Concomitant Medications</i>	25

Overview of training materials

- Training material intended to provide clarity on key aspects of the guideline in order to facilitate a harmonized interpretation and implementation by industry and regulators in the ICH and non-ICH regions
- Training material does not provide additional guidance beyond E17

Overview of Training material

General modules

- Animated video; Main message of MRCTs
- Module 1; Overview of training material/Basic principles

Technical modules

- Module 2; Preconsideration of regional variability when recruiting diverse populations in global development
- Module 3; Selection of doses
- Module 4; Sample size allocation
- Module 5; Pooling strategies
- Module 6; Evaluation of consistency
- Module 7; Selection of comparators

Table of Contents and related training modules

1. INTRODUCTION	1
1.1. Objectives of the Guideline	1
1.2. Background	1
1.3. Scope of the Guideline	2
1.4. Basic Principles	2
	Module 1/video
2. GENERAL RECOMMENDATIONS IN THE PLANNING AND DESIGN OF MRCTS	3
2.1 Strategy-related Issues	3
2.1.1 <i>The Value of MRCTs in Drug Development</i>	3
2.1.2 <i>Good Clinical Practice (GCP) Requirements and MRCTs</i>	6
2.1.3 <i>Scientific Consultation Meetings with Regulatory Authorities</i>	6
2.2 Clinical Trial Design and Protocol-related Issues	7
2.2.1 <i>Pre-consideration of Regional Variability and its Potential Impact on Efficacy and Safety</i>	7
	Module 2
2.2.2 <i>Subject Selection</i>	9
2.2.3 <i>Selection of Doses for Use in Confirmatory MRCTs</i>	10
	Module 3
2.2.4 <i>Choice of Endpoints</i>	11
2.2.5 <i>Sample Size Planning</i>	13
	Module 4/5
2.2.6 <i>Collecting and Handling of Efficacy and Safety Information</i>	18
2.2.7 <i>Statistical Analysis Planning</i>	20
	Module 6
2.2.8 <i>Selection of Comparators</i>	23
	Module 7
2.2.9 <i>Handling Concomitant Medications</i>	25
3. GLOSSARY	26

Finally...

- We hope this training material will be useful and help you to understand and use the E17 guideline in your planning and/or assessment of multiregional clinical trials

